On Jan. 27, 2021, Vaxart announced health care economic findings published in the American Journal of Preventative Medicine. Computational modeling simulated norovirus infection and transmission in a community setting showed that a potential norovirus vaccine can avert symptomatic cases and result in cost savings.

The study found that vaccination against the norovirus can reduce the economic burden of the virus and is cost effective even if priced at $500 per course when vaccinating children under 5 and older adults, a much higher value than previously estimated.